We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Hangzhou Xinhai Biotechnology Co., LTD., located in Binjiang District, Hangzhou, is a biotechnology company specializing in the research, development, production and sales of pharmaceutical enzyme preparations and chiral chemicals. In 2016, it was selected as the "5050 Plan" of Hangzhou High-tech Zone (Binjiang) and the "Blue Plan" of Hangzhou Science and technology start-up enterprise Cultivation project, and was recognized as a science and technology enterprise in Zhejiang Province; In 2017, it was selected as Hangzhou High-tech Enterprise; In 2019, it was recognized as a national high-tech enterprise. The main purpose of the company is to develop advanced biotechnology for the preparation of high value-added fine chemicals.
The company is located in Tianhe Bio-pharmaceutical Industrial Park, Binjiang District, Hangzhou, has built more than 600 square meters of laboratory and pilot scale amplification platform, equipped with 250L fermenter, 100L reactor, 50L rectification tower and other equipment, R & D equipment investment of 5 million yuan. The company has applied for 6 invention patents and has obtained 5 authorized invention patents; There are 42 registered trademarks, and all products have independent intellectual property rights.
The first batch of products of the company, chiral phenyl ethanol and its derivatives, lipase XHlip-O (for special oil processing), lipase XHlip-F (for the preparation of chiral chemicals) have achieved large-scale production, and the development prospect is good. And as a starting point, to create a research and development, market development and capital operation as one of the team. And continue to seek cooperation with universities and research institutes, with the combination of independent innovation and open innovation, rapid growth into an innovative biotechnology high-tech company.
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
